The Genome

CMECNE

Consensus Guideline: Treatment Options for Hereditary Breast Cancer

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the recommended surgical treatment for hereditary breast cancer
2. Describe the recommended medical treatment for hereditary breast cancer

Estimated time to complete activity: .25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from through , participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is .25 contact hours.

Read Disclaimer & Fine Print

SUMMARY:

American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO) have published a guideline for management of individuals with hereditary breast cancer. The guideline was developed to standardize care among individuals carrying a pathogenic mutation, with a focus on BRCA1/2, PALB2, CHEK2, TP53 and ATM germline mutations. The guideline was created by a consensus panel of 52 members, and funded by ASCO.

Background

The majority of breast cancer is sporadic (no family history)
15 to 20% of breast cancer is familial (clustering with significant family history, but no pathogenic mutation identified)
5 to 10% of breast cancer is hereditary and associated with a germline mutation
High penetrance genes such as BRCA1/2 confer a lifetime breast cancer risk of 70%
Moderate penetrance genes confer a lower risk
- PALB2: 35 to 60%
- ATM and CHEK2: 25 to 30% mutations

Key Recommendations

Surgical treatment

Patients with newly diagnosed hereditary breast cancer can be offered breast-conserving therapy (BCT)
Patients who are BRCA1/2 carriers are at increased risk of contralateral breast cancer (CBC)
Discuss the option of bilateral mastectomy (with contralateral risk-reducing mastectomy (CRRM))
- Consideration of family history, age at diagnosis, comorbidities, life expectancy and ability for the patient to undergo breast surveillance should be a part of this conversation
Patients who do not have bilateral mastectomy
- Offer high-risk screening of the remaining breast tissue with annual mammogram and magnetic resonance imaging
For patients who request CRRM
- Nipple-sparing mastectomy (NSM) is a reasonable approach
- There is limited evidence for CRRM in patients with moderate-penetrance genes (PALB2, ATM, and CHEK2) | Additional factors can be considered such as age at diagnosis and family history
TP53 mutation carriers
- Offer mastectomy because radiation therapy is contraindicated unless the risk of locoregional recurrence is high

Medical Treatment

Advanced BRCA-associated breast cancer
- Platinum agents are recommended versus taxanes
- There are no data to address platinum efficacy in other germline mutations
Poly ADP-ribose polymerase (PARP) inhibitors
- Recommended for metastatic HER2-negative BRCA-associated breast cancer as an alternative to chemotherapy for first- to third-line therapy
- No evidence exists to support the use of PARP inhibitor in patients with moderate penetrance genes

Note: A recent publication in the NEJM supports the role for adjuvant olaparib, a PARP inhibitor, for the treatment of HER2-negative early breast cancer specifically for patients with germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants

Learn More – Primary Sources

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Take a post-test and get CME credits

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

< Previous

All The Genome Posts

Next >

Consensus Guideline: Treatment Options for Hereditary Breast Cancer